<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1-3; <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (AraC) 200 mg/m2/day, days 1-7; cladribine (2-CdA) 5 mg/m2/day, days 1-5, 400 untreated adult <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> patients (including 63 with preceding <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>), aged 45 (16-60) years were randomized to either DAC-7 (n=200) or <z:mp ids='MP_0000273'>DA</z:mp>-7 (without 2-CdA, n=200) </plain></SENT>
<SENT sid="1" pm="."><plain>The overall CR rate equaled 72% for DAC-7 and 69% for <z:mp ids='MP_0000273'>DA</z:mp>-7 arm (P=NS) </plain></SENT>
<SENT sid="2" pm="."><plain>After a single course of DAC-7 induction, the CR rate equaled 64% and was significantly higher compared to 47% in the <z:mp ids='MP_0000273'>DA</z:mp>-7 arm (P=0.0009) </plain></SENT>
<SENT sid="3" pm="."><plain>Median hospitalization time during the induction was 7 days shorter for DAC-7 compared to the <z:mp ids='MP_0000273'>DA</z:mp>-7 group (33 vs 40 days, P=0.002) </plain></SENT>
<SENT sid="4" pm="."><plain>Toxicity was comparable in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>The probability of 3-year <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) for DAC-7 and <z:mp ids='MP_0000273'>DA</z:mp>-7 group equaled 43 and 34%, respectively (P=NS) </plain></SENT>
<SENT sid="6" pm="."><plain>There was a trend toward higher <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> rate for patients aged &gt;40 years receiving DAC-7 compared with <z:mp ids='MP_0000273'>DA</z:mp>-7 regimen (44 vs 28%, P=0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>This study proves that addition of 2-CdA increases antileukemic potency of DNR+AraC regimen, thus resulting in a higher CR rate after one induction cycle when compared to <z:mp ids='MP_0000273'>DA</z:mp>-7, without additional toxicity </plain></SENT>
<SENT sid="8" pm="."><plain>It shortens hospitalization time and may improve long-term survival in patients aged &gt;40 years </plain></SENT>
</text></document>